Trials / Terminated
TerminatedNCT02142192
Natalizumab Subcutaneous Immunogenicity and Safety Study
A Multicenter, Open-Label Immunogenicity and Safety Study of Subcutaneous Natalizumab 300 mg Administered to Subjects With Relapsing Multiple Sclerosis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the immunogenicity of natalizumab (BG00002) 300 mg subcutaneous (SC) administered to participants with relapsing multiple sclerosis (RMS). The secondary objectives of the study are to evaluate the safety of natalizumab SC injections and to evaluate the efficacy of natalizumab SC injections on relapses and on new magnetic resonance imaging (MRI) lesions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | natalizumab | Administered as specified in the treatment arm |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2015-06-04
- Completion
- 2015-06-04
- First posted
- 2014-05-20
- Last updated
- 2024-06-03
Locations
2 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02142192. Inclusion in this directory is not an endorsement.